{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-070566","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.406337+00:00","generated_at":"2026-06-01T05:36:08.930075+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Cue Biopharma appoints Michael J. Fox to board; grants 48,800-share option","bullets":["Michael J. Fox appointed to Board and Compensation Committee effective June 5, 2024.","Received option to purchase 48,800 shares vesting over three years (1/3 at one year, then quarterly).","Stockholders elected all 7 director nominees; Passeri received 13,099,740 for, 765,119 withheld.","Ratified RSM US LLP as auditor for FY2024 with 32,418,349 for, 1,635,231 against.","Non-binding say-on-pay passed with 11,745,009 for, 1,924,707 against, 20,311,373 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-070566","json":"https://secwatch.observer/filing/0000950170-24-070566.json","markdown":"https://secwatch.observer/filing/0000950170-24-070566.md","text":"https://secwatch.observer/filing/0000950170-24-070566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/0000950170-24-070566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/cue-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:36:08.930075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0727455f90","claim":"Michael J. Fox was appointed as Director at Cue Biopharma, Inc..","evidence_excerpt":"On June 5, 2024, Michael J. Fox was appointed to the board of directors (the “Board”) and the Compensation Committee of the Board of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/0000950170-24-070566-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}